• About us
• Contact

Advertisement

Organisation › Details

Mérieux (Group)

With extensive experience in industrial biology, Institut Mérieux contributes to serving medicine and public health across the globe. For the fight against infectious diseases and cancer, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, and food safety and nutrition. With its three business activities- bioMérieux, Transgene and Silliker-Institut Mérieux has the potential to provide answers to the new challenges of public health globally: personalized medicine and new therapies, infectious diseases and cancer, food safety and nutrition. bioMérieux, listed on NYSE Euronext Paris and 59% owned, is based in Marcy l'Etoile (France). World leader of in vitro diagnostics and industrial microbiological controls. Transgene: Based in Strasburg (France), this biotech company is 55% controlled and is listed on NYSE Euronext Paris. It develops immunotherapy products for the treatment of cancer and infectious diseases. www.transgene.fr Silliker is a privately-owned company, 86% controlled, based in Chicago (United States), encompassing a network of nearly 50 laboratories dedicated to improving food safety and nutrition. www.silliker.com Institut Mérieux employs nearly 10,000 people in the service of public health worldwide and generates net sales of over 1.4 billion Euros. *

 

	Start	1992-07-01 existent
	Industry	in vitro diagnostics (IVD)
	Industry 2	food analysis (food testing)
	Region	Lyon
	Country	France
	City	n. a. Lyon
		Address record changed: 2020-12-02
Basic data	Employees	G: 5,001 to 10,000 (2010-08-12)
	Currency	EUR
	Annual sales	1,400,000,000 (net sales (2009) 2009-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Mérieux (Group)

• [1] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
• [2] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
• [3] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
• [4] Weezion SAS. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
• [5] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
• [6] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
• [7] bioMérieux S.A.. (4/24/19). "Press Release: bioMérieux – First-Quarter 2019 Business Review". Marcy l’Étoile....
• [8] bioMérieux S.A.. (4/15/19). "Press Release: “Global-PPS”, a Survey of Antibiotic Use and Bacterial Resistance in Hospitals Worldwide, Tops the 200,000 Patients". Marcy l’Étoile & Antwerp....
• [9] bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile....
• [10] bioMérieux S.A.. (3/19/19). "Press Release: Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury". Deerfield, IL & Marcy l’Etoile....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.